Conjugates for treating diseases caused by PSMA expressing cells
US9636413B2 · kind B2 · utility
30Cited by
89References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2013 |
| Grant date | May 2, 2017 |
| Priority date | — |
| Expiry date | Nov 14, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.